Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Net Cash Flow (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Net Cash Flow for 14 consecutive years, with $22.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 321.27% year-over-year to $22.9 million, compared with a TTM value of -$2.3 million through Dec 2025, up 92.66%, and an annual FY2025 reading of -$1.9 million, down 120.17% over the prior year.
  • Net Cash Flow was $22.9 million for Q4 2025 at Karyopharm Therapeutics, up from -$1.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $63.7 million in Q4 2022 and bottomed at -$70.4 million in Q2 2022.
  • Average Net Cash Flow over 5 years is -$3.4 million, with a median of -$3.1 million recorded in 2021.
  • The sharpest move saw Net Cash Flow skyrocketed 1107.8% in 2021, then tumbled 4458.21% in 2022.
  • Year by year, Net Cash Flow stood at $57.1 million in 2021, then increased by 11.48% to $63.7 million in 2022, then plummeted by 86.62% to $8.5 million in 2023, then crashed by 221.25% to -$10.3 million in 2024, then skyrocketed by 321.27% to $22.9 million in 2025.
  • Business Quant data shows Net Cash Flow for KPTI at $22.9 million in Q4 2025, -$1.1 million in Q3 2025, and -$412000.0 in Q2 2025.